Health insurer Centene to stop participating in Arkansas’ Medicaid expansion
Centene Corp. will withdraw from Arkansas’ Medicaid expansion program, ARHOME, starting next year. This move will impact approximately one-third of the 211,000 Arkansans currently enrolled in Centene’s three plans. The Department of Human Services will transfer these enrollees to other eligible plans offered by BlueCross BlueShield.
Centene plans to exit Arkansas’ Medicaid expansion program in 2027
Centene Corp., one of the two main providers of health insurance marketplace plans in Arkansas, announced its intention to withdraw from the state's Medicaid expansion program (ARHOME) starting in 2027. This move will affect approximately 70,000 Arkansans currently covered by Centene plans, who will be transitioned to other providers. Following Centene's departure, Arkansas Blue Cross and Blue Shield will be the sole participating company in the ARHOME program.
Centene Corp evaluates its strategy as US health coverage needs evolve
Centene Corp is re-evaluating its strategy and cost structure in response to the changing regulatory and reimbursement landscape within the US managed care sector. The company primarily focuses on government-sponsored health programs like Medicaid, Medicare, and Affordable Care Act marketplace plans, necessitating strict operational discipline and effective risk management. Centene's business model integrates health plan administration, provider network management, and care coordination to provide comprehensive health solutions.
Can Centene's Fraud Prevention Strategy Support Margin Recovery?
Centene Corporation is enhancing its fraud prevention efforts through advanced analytics and AI-enabled tools to improve profitability in its government-sponsored healthcare businesses. This strategy, particularly effective in Medicaid, helped increase Q1 2026 adjusted EPS by 16.2% and improved the Medicaid health benefits ratio. These initiatives aim to strengthen cost controls and provide a competitive advantage, with competitors like UnitedHealth Group and Elevance Health also focusing on similar strategies.
Can Centene's Fraud Prevention Strategy Support Margin Recovery?
Centene Corporation is enhancing its fraud prevention strategy by integrating advanced analytics and AI, aiming to improve profitability in its government-sponsored healthcare businesses. These efforts have already contributed to improved Medicaid margins and a raised adjusted EPS guidance for 2026. The company's focus on payment integrity and AI-driven analytics is expected to strengthen margin recovery and provide a competitive advantage, despite ongoing healthcare cost challenges.
Can Centene's Fraud Prevention Strategy Support Margin Recovery?
Centene Corporation is enhancing its fraud, waste, and abuse prevention strategies, using advanced analytics and AI, to improve profitability in its government-sponsored healthcare businesses. These efforts have already contributed to improved Medicaid margins in Q1 2026, leading to raised EPS guidance for the year. Competitors like UnitedHealth Group and Elevance Health are also focusing on similar AI-driven payment integrity measures.
Ambetter health plans from Centene Corp. - a key Obamacare product for US families
Ambetter health plans by Centene Corp. are a major product line on the Affordable Care Act (ACA) marketplaces, providing essential health benefits to millions of US families. The plans offer tiered options (bronze, silver, gold), digital tools, and focus on affordability for individuals and families without employer-sponsored coverage. Ambetter's presence across many states and its integration with ACA subsidies make it a significant player in the national health insurance landscape, affecting both consumers and Centene's financial performance.
Centene Corp. focuses on managed care growth as health plans evolve
Centene Corp. is a leading U.S. managed care company primarily serving Medicaid, Medicare, and Affordable Care Act marketplace members. The company emphasizes refining its portfolio and cost structure for sustainable growth within government-sponsored health programs, relying on operational efficiency and robust cost management strategies. Its business model is sensitive to U.S. healthcare policy and macroeconomic factors, which influence its membership and revenue, making ongoing adaptation crucial.
Health Insurance Providers Stocks Q1 Recap: Benchmarking Centene (NYSE:CNC)
This article reviews the Q1 earnings for health insurance providers, highlighting Centene (NYSE:CNC) as a top performer. It discusses Centene's strong revenue and EPS beat, along with CVS Health's exceptional quarter. Conversely, Cencora (NYSE:COR) is noted for a weaker performance, while Clover Health (NASDAQ:CLOV) and Progyny (NASDAQ:PGNY) also showed strong results and growth.
Centene Corp. focuses on managed care growth as investors watch its US health coverage footprint
Centene Corp. is a major player in the US managed care and government-sponsored health plan market, focusing on Medicaid, Medicare, and marketplace coverage. The company's financials are significantly influenced by membership growth, medical cost management, and policy changes. Centene uses care coordination, digital tools, and data analytics to optimize health outcomes and manage costs within its diverse health plans for individuals and employer groups.
Molina Healthcare outlines its managed care strategy as a US Medicaid specialist
Molina Healthcare specializes in government-sponsored health plans, primarily focusing on Medicaid, Medicare, and Affordable Care Act (ACA) marketplaces. The company operates as a managed care organization, contracting with state agencies to provide health benefits to vulnerable populations, emphasizing care coordination and cost control. Its business model, which includes a diversified portfolio of government-related health plans, is attractive to investors interested in publicly funded healthcare.
Centene Corp. highlights its managed care role in US healthcare. Investors look at long-term growth
Centene Corp. is a major US managed care provider, focusing on government-sponsored healthcare programs like Medicaid and Medicare Advantage, serving millions of members. The company's business model revolves around coordinating and financing healthcare services for public entities, making its long-term prospects tied to government policies, demographic trends, and healthcare spending. Investors view Centene as an exposure to government-backed health programs, with its performance influenced by enrollment, cost control, and policy developments.
HUM - Humana Inc Latest SEC Filings
This article provides the latest SEC filing information and comprehensive financial data for Humana Inc. (HUM). It details various financial metrics such as market cap, income, sales, P/E ratios, dividend information, and performance indicators, alongside insider ownership and institutional transactions. The data reflects the company's financial health and stock performance as of July 2, 2024.
Can Centene's Integrated Healthcare Model Support Earnings Growth?
Centene's integrated healthcare model, combining government health plans with clinical, pharmacy, and community-based services, is expected to support its earnings growth. The company serves 26.3 million members, allowing for economies of scale, and is leveraging technology and data analytics to manage costs and improve outcomes. Despite regulatory challenges, Centene's investments in technology and clinical programs are set to drive margin recovery and sustainable long-term earnings growth.
Top Momentum Stocks to Watch: Centene Corporation (CNC) Leads with Strong RSI
Centene Corporation (CNC) is highlighted as a top momentum stock with a strong Relative Strength Index (RSI) of 67 and a high Quant rating of 4.94, despite historical trends suggesting July can be challenging for momentum stocks. The company, a significant player in the managed healthcare sector with a $33.75 billion market cap, has a GF Score™ of 74, indicating solid performance, particularly in profitability. However, investors are advised to exercise caution due to a low growth rank and significant insider selling, totaling $5.2 million over the past three months.
Can Centene's Integrated Healthcare Model Support Earnings Growth?
Centene Corporation's integrated healthcare model, combining government-sponsored health plans with coordinated clinical services, is supporting its earnings potential by effectively managing medical costs and improving health outcomes. The company is leveraging technology and data, including AI, to enhance operational capabilities and pricing decisions. Despite regulatory challenges, these efforts, along with its strong first-quarter 2026 performance and raised EPS guidance, position Centene for sustainable long-term growth, competing with giants like UnitedHealth and Elevance Health.
Molina Healthcare focuses on managed care growth as investors watch US health coverage trends
Molina Healthcare, a US-based managed care company, specializes in providing health insurance services through government programs like Medicaid and Medicare. The company's growth and profitability are closely tied to enrollment levels, effective management of medical costs relative to fixed payments, and the ever-changing policy environment surrounding public health coverage. Investors closely monitor these factors, along with regulatory developments and industry performance, to assess Molina Healthcare's financial health and future prospects.
Form 4 Centene Corp For: 1 July By Investing.com
This article from Investing.com announces the filing of a Form 4 for Centene Corp on July 1st. It also includes various financial market data such as indices, commodities, bonds, and stocks, along with trending news and market movers. The content primarily serves as a placeholder for a financial news update and features extensive financial data and news headlines.
Form 4 Centene Corp For: 1 July By Investing.com
This article from Investing.com announces a Form 4 filing for Centene Corp (CNC) for July 1st. It serves as a brief notice of the SEC filing for the healthcare enterprise.
RBC Initiates Centene (CNC) Coverage and Says the Worst of 2025 Is Firmly in the Rearview Mirror
RBC Capital analyst Ben Hendrix initiated coverage of Centene Corporation (NYSE:CNC) with a Sector Perform rating and a $70 price target. Hendrix noted that Centene is showing early signs of recovery in 2026 after a challenging 2025 marked by high medical costs and policy uncertainty. The analyst anticipates improving margins due to Medicaid reimbursement rate adjustments and favorable pricing changes in Centene's ACA exchange business, and potential for 2026 EPS to exceed guidance.
Centene Corp. stock outperforms competitors on strong trading day
Centene Corp. (CNC) saw its stock rise by 6.48% to $68.35 on Wednesday, despite a general market downturn where the S&P 500 Index and Dow Jones Industrial Average both experienced slight declines. This performance broke a two-day losing streak for the company. The strong trading day for Centene Corp. indicates a notable outperformance compared to its market competitors.
Centene Corp. highlights managed care strategy as investors assess long-term growth
Centene Corp. is a major U.S. managed care provider focused on government-sponsored health programs like Medicaid, Medicare, and health insurance marketplaces. The company's long-term growth is influenced by the balance between growth, profitability, and regulatory stability within these highly regulated sectors. Investors evaluate Centene's ability to manage medical costs, achieve administrative efficiency, and adapt to policy changes, alongside its strategies for diversification and scale, to assess its financial performance and competitive position.
Centene Corp stock hits 52-week high at 66.59 USD By Investing.com
Centene Corp (CNC) stock has reached a 52-week high of $66.59, trading just below its peak, driven by a 90.02% increase over the past year. InvestingPro analysis suggests the stock is undervalued and has "GREAT" financial health. Recent developments include new analyst coverage with a "Sector Perform" rating and a $70 price target, the appointment of Lauren M. Tyler to its board, and cost-cutting measures such as voluntary employee buyouts.
Centene Corp stock hits 52-week high at 66.59 USD By Investing.com
Centene Corp (CNC) stock has reached a new 52-week high of $66.59, reflecting a 90.02% increase over the past year. InvestingPro analysis suggests the stock is currently undervalued and holds a "GREAT" financial health score. Recent company developments include RBC Capital initiating coverage with a Sector Perform rating, a new board appointment, and a cost-cutting initiative involving employee buyouts.
Centene Corp stock hits 52-week high at 66.59 USD
Centene Corp stock has reached a new 52-week high of $66.59, reflecting a 90.02% increase over the past year. InvestingPro analysis suggests the stock is undervalued with "GREAT" financial health. Recent developments include new analyst coverage, a board appointment, and a cost-cutting buyout offer for employees.
US firms score roles on the $69bn CVS Health Aetna merger
McDermott Will & Schulte, a global law firm, advised CVS Health Corp. on its $69 billion acquisition of insurer Aetna Inc., a deal expected to significantly impact the US healthcare sector. The acquisition was one of the largest M&A transactions in 2017. Several partners from McDermott's offices in Washington, DC, Chicago, and Dallas were involved in this major deal.
Humana, Centene lead healthcare rally in Q2 over Medicare Advantage optimism
The healthcare sector rallied in Q2, primarily driven by optimism surrounding proposed increases in Medicare Advantage payments. This led to significant outperformance by managed care companies like Humana and Centene, despite the sector lagging the broader markets due to concerns over drug pricing and policy uncertainty. The sustainability of this rally and the impact of other healthcare themes remain key risks.
Ambetter from Centene Corp. - one of the largest ACA plan brands in the US
Ambetter, Centene's Affordable Care Act (ACA) health insurance brand, is a prominent provider of marketplace health plans in numerous U.S. states. The article details Ambetter's offerings, including various metal tiers and a focus on primary care, and explains its role in Centene's overall financial performance. It also touches on Ambetter's competitive landscape, regulatory context, and member experience, highlighting its significance for Centene Corp. investors.
Plus Therapeutics rebrands as Cerenome, ticker CNSY starts Aug. 3
Plus Therapeutics (Nasdaq: PSTV) announced a rebranding to Cerenome with its ticker changing to CNSY, effective August 3, 2026. The company affirmed its 2026 milestone guidance, providing updates on REYOBIQ clinical trials, commercial expansion of its CNSide diagnostic platform, and the initiation of an AI and data strategy. Key progress includes increased CNSide covered lives to 126 million, Medicare enrollment, and advancements in manufacturing scale-up for REYOBIQ.
Morgan Stanley raises UnitedHealth stock price target on utilization
Morgan Stanley has raised its price target for UnitedHealth Group (NYSE:UNH) to $468 from $453, maintaining an Overweight rating, citing favorable utilization trends and strong Optum Health execution. The firm expects above-consensus second-quarter earnings, set to be reported on July 16, 2026, marking the start of the managed care earnings season. UnitedHealth has also consistently increased its dividend for 16 consecutive years.
Centene Corp. consensus picture on Wall Street, shares trade on the NYSE
Centene Corp. opens Tuesday with a steady analyst consensus on Wall Street, focusing on earnings expectations, valuation, and positioning among U.S. health insurance peers. The company, a U.S. managed-care and Medicaid specialist, is covered by major research houses like Goldman Sachs and JPMorgan. Analysts monitor metrics such as revenue growth, operating margins, and price-to-earnings multiples against competitors like UnitedHealth Group.
Centene Corp. stock underperforms Monday when compared to competitors
Centene Corp. (CNC) shares decreased by 1.81% on Monday, closing at $64.54, despite a strong overall market performance where the S&P 500 Index rose by 1.18% and the Dow Jones Industrial Average increased by 0.59%. This decline ended a two-day winning streak for the stock.
ACA Marketplace premiums might see a double-digit spike in 2027
A preliminary analysis indicates that ACA Marketplace premiums could see double-digit rate hikes in 2027 in some states. This is primarily attributed to the lapse of enhanced premium tax credits, uncertainty surrounding the Notice of Benefit and Payment Parameters (NBPP), and rising healthcare costs. These factors are expected to lead to smaller, sicker risk pools and increased financial burdens for many middle-income earners and uninsured individuals.
Best Growth Stocks to Buy for June 29th
Zacks Investment Research has identified three growth stocks—Celestica Inc., Cboe Global Markets, Inc., and Centene Corporation—as top buys for June 29th. These companies all hold a Zacks Rank #1 and exhibit strong growth characteristics, including favorable PEG ratios compared to their industries and positive revisions in current year earnings estimates. Celestica and Centene boast a Growth Score of B, while Cboe Global Markets achieved an A.
Best Growth Stocks to Buy for June 29th
This article identifies three top-ranked growth stocks for June 29th, according to Zacks Investment Research. The selected companies are Celestica Inc. (CLS), Cboe Global Markets, Inc. (CBOE), and Centene Corporation (CNC), all of which carry a Zacks Rank #1 and exhibit strong growth characteristics, including favorable PEG ratios and increased earnings estimates. The analysis suggests these stocks offer potential for investors seeking growth opportunities.
Best Growth Stocks to Buy for June 29th
The article identifies three growth stocks with "buy" ranks for June 29th: Celestica Inc. (CLS), Cboe Global Markets, Inc. (CBOE), and Centene Corporation (CNC). These companies are highlighted for their strong growth characteristics, including increased Zacks Consensus Estimates for current year earnings and favorable PEG ratios compared to their respective industries. Each stock has a Zacks Rank #1 and a Growth Score of either A or B.
Molina Healthcare, Inc.(NYSE: MOH) dropped from Russell 1000 Value-Defensive Index
Molina Healthcare, Inc. (NYSE: MOH) has been removed from the Russell 1000 Value-Defensive Index. This announcement comes amid several other recent reclassifications for the company, including being dropped from the Russell 1000 Growth-Defensive and Russell 3000E Growth Benchmarks. Molina Healthcare is a managed healthcare services provider for Medicaid, Medicare, and state insurance marketplaces.
Ambetter Marketplace Plans from Centene Corp. - thinner margins and home-state focus
Centene Corp.'s Ambetter Marketplace Plans, which provide ACA coverage, are facing significant revenue headwinds due to expiring subsidies in 2026, leading to a 36% drop in Q1 2026 membership. Despite anchoring Centene's presence on ACA exchanges and generating substantial premium revenue, the company is increasingly relying on its Medicaid and Medicare segments for growth as Ambetter adapts to a leaner membership base. The plans are noted for their predictability in cost for consumers, though network breadth can be a source of frustration.
Molina Healthcare, Inc.(NYSE: MOH) dropped from Russell 1000 Growth Benchmark
Molina Healthcare, Inc. (NYSE: MOH) has been removed from the Russell 1000 Growth Benchmark. This news comes amidst other recent updates for the company, including analyst ratings, contract wins, and insider transactions. Molina Healthcare provides managed healthcare services primarily under Medicaid, Medicare, and state insurance marketplaces.
BetterInvesting Names Deckers Outdoor and Euronet for September 2026
BetterInvesting Magazine has selected Deckers Outdoor Corp. as its "Stock to Study" and Euronet Inc. as its "Undervalued Stock" for the September 2026 issue. The non-profit organization provides educational resources, including investment strategies and a six-step investing guide, to help investors make informed decisions. Wall Street analysts maintain a positive outlook on Deckers Outdoor, with price target adjustments reflecting confidence in brands like HOKA.
Centene cautious on workforce plans, shares hold steady in S&P 500 healthcare group
Centene Corporation is under scrutiny for planned workforce reductions while RBC Capital initiates coverage with a "Sector Perform" rating and a $70 price target. Despite potential execution risks in Medicaid and Marketplace operations, the managed-care stock remains a key player in the S&P 500 healthcare sector, with shares showing positive year-to-date performance. The company's strategy involves streamlining operations for cost savings and margin expansion.
Centene (CNC) Appoints Lauren M. Tyler To Board With JPMorgan Leadership Experience
Centene (CNC) has appointed Lauren M. Tyler to its Board of Directors, bringing extensive leadership experience from JPMorgan Chase & Co. in finance, audit, and human capital strategy. This appointment is expected to influence board-level priorities such as capital allocation, risk oversight, and executive oversight, particularly as Centene focuses on cost structure reviews and membership shifts. Investors are advised to monitor future disclosures and governance updates to understand the impact of her role on the company's long-term decision-making and operational efficiency.
3 US Value Stocks Worth A Closer Look As Inflation Holds At 4.1%
Amidst 4.1% inflation, shifting Fed rate expectations, and volatile energy prices, this article highlights three US value stocks: Ategrity Specialty Insurance Company Holdings (ASIC), Upbound Group (UPBD), and Centene (CNC). These companies stand out due to their alignment with current macroeconomic conditions, offering unique value propositions like specialty underwriting, high dividend yields, or strong revenue bases, despite various risks. The analysis encourages investors to delve deeper into their financial specifics and market sensitivities.
Centene steady in Medicaid space, shares track S&P 500 health peers
Centene Corp. continues to operate as a mid-cap managed-care provider, primarily focused on Medicaid and Affordable Care Act exchange plans, distinguishing it from more diversified peers like UnitedHealth and Elevance. The company's stock performance and investor discussions are influenced by Medicaid redeterminations and Medicare Advantage margins, with current market capitalization around $34 billion.
States seek to lower drug prices by targeting the companies that manage them for health plans
States across the U.S. are increasingly targeting pharmacy benefit managers (PBMs) to lower prescription drug costs amid consumer concerns about affordability. Legislators in multiple states have passed laws to limit PBM compensation, set minimum pharmacist payments, and increase disclosure requirements, with some measures facing legal challenges from PBMs like CVS Health. While PBMs claim they help reduce drug costs, critics argue they contribute to high prices and squeeze independent pharmacies, leading to a complex debate with federal regulatory efforts also underway.
States seek to lower drug prices by targeting the companies that manage them for health plans
States are taking action to lower drug prices by regulating pharmacy benefit managers (PBMs), which oversee prescription coverage for health insurers. Legislation passed in at least a dozen states aims to limit PBM compensation, establish minimum payments for pharmacists, and increase transparency. This movement is a response to consumer concerns about medication affordability, with some PBMs, like CVS, actively fighting these new regulations through lawsuits and advertising campaigns.
Humana stock hits 52-week high at 381.2 USD By Investing.com
Humana Inc. (NYSE: HUM) stock has reached a new 52-week high of $381.12, reflecting a 59% return over the past year and substantial gains year-to-date. The company's strong performance is supported by its strategic initiatives, including a new statewide Medicaid contract in Illinois and the sale of its minority interest in Gentiva for $900 million. Analysts maintain ratings from "Overweight" to "Neutral", highlighting investor confidence and the stock's potential for further upside despite its recent surge.
Humana stock hits 52-week high at 381.2 USD
Humana Inc. (NYSE:HUM) stock reached a 52-week high, trading at $381.12, reflecting a 59% return over the past year. The healthcare giant also announced it has been selected for Illinois' statewide Medicaid managed care program and agreed to sell its minority interest in Gentiva for approximately $900 million. Analyst firms have reiterated ratings, with Cantor Fitzgerald maintaining an Overweight rating and UBS a Neutral rating, based on these strategic developments.
Molina Healthcare guidance and Medicaid focus, shares in S&P 500 spotlight
Molina Healthcare reaffirmed its full-year guidance, emphasizing its disciplined strategy and focus on Medicaid managed care. The S&P 500 company reported a 17% increase in Q1 2024 revenue, with strong membership growth in Medicaid and Medicare segments. Analysts maintain a positive outlook, supported by stable medical cost ratios and a robust pipeline of state contracts.
Centene Corp. stock outperforms competitors on strong trading day
Centene Corp. (CNC) saw its stock rise by 2.86% to $64.77 on Thursday, outperforming the mixed market performance where the Dow Jones Industrial Average gained 0.14% and the S&P 500 Index fell 0.01%. This increase broke a two-day losing streak for the company, highlighting a strong trading day for Centene.
